EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

The Relationship between SLC22A16 Gene Polymorphism and Hematological Toxicity in Breast Cancer Patients Receiving Doxorubicin-Based Chemotherapy

SRI MELINDA KABAN, Siti Syarifah, Yunita Sari Pane, Tri Widyawati

Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI) · 12.02.2025 · 7 (1) · 27-33

DOI: 10.32734/jetromi.v7i1.18520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI), online erschienen am 12.02.2025. Verfasst von SRI MELINDA KABAN und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug transporter polymorphisms are widely associated with the risk of toxicity in many chemotherapy drugs in cancer. This paper aims to assess the relationship of polymorphisms of this transporter, namely SLC22A16, which are associated with side effects of Doxorubicin-based chemotherapy drugs, namely hematological toxicity (anemia, neutropenia, leukopenia and thrombocytopenia) in breast cancer patients.

Method

This cross-sectional study will be conducted by testing polymorphism using the ARMS PCR method, which will assess the distribution of AA, AG, and GG genotypes.

Result

Most patient ages are under 50 years (55%), with overweight BMI (41,7%) and Batak ethnicity (43,3%). There is no relationship between SLC22A16 Gene Polymorphism and Hematological Toxicity in Breast Cancer Patients Receiving Doxorubicin-Based Chemotherapy

Zitieren

APA

KABAN, S. M., Syarifah, S., Pane, Y. S., & Widyawati, T. (2025). The Relationship between SLC22A16 Gene Polymorphism and Hematological Toxicity in Breast Cancer Patients Receiving Doxorubicin-Based Chemotherapy. Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI), 7(1), 27-33. https://doi.org/10.32734/jetromi.v7i1.18520

Vancouver

KABAN SM, Syarifah S, Pane YS, Widyawati T. The Relationship between SLC22A16 Gene Polymorphism and Hematological Toxicity in Breast Cancer Patients Receiving Doxorubicin-Based Chemotherapy. Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI). 2025;7(1):27-33. doi:10.32734/jetromi.v7i1.18520

BibTeX
@article{KABAN2025,
  author = {KABAN, SRI MELINDA and Syarifah, Siti and Pane, Yunita Sari and Widyawati, Tri},
  title = {The Relationship between SLC22A16 Gene Polymorphism and Hematological Toxicity in Breast Cancer Patients Receiving Doxorubicin-Based Chemotherapy},
  journal = {Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI)},
  year = {2025},
  volume = {7},
  number = {1},
  pages = {27--33},
  doi = {10.32734/jetromi.v7i1.18520}
}
Kostenlos starten →